1:34 PM
Jul 21, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Debiopharm completes enrollment in Phase I/II of Debio 1143 for SCCHN

Debiopharm Group (Lausanne, Switzerland) completed enrollment of 96 patients with previously untreated, locally advanced squamous cell carcinoma of the head and neck (SCCHN) in the Phase II portion of a double-blind, placebo-controlled, French and Swiss Phase I/II trial of oral Debio 1143 (AT-406) in combination with chemo-radiation therapy (CRT). Debio 1143 is a small molecule inhibitor of apoptosis (IAP).

The trial is evaluating Debio 1143 daily...

Read the full 307 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >